Abraham Ceesay - 05 Aug 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
President
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
05 Aug 2022
Net transactions value
-$1,231,751
Form type
4
Filing time
09 Aug 2022, 20:59:18 UTC
Previous filing
11 Feb 2022
Next filing
17 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $506,044 +38,424 $13.17 38,424 05 Aug 2022 Direct F1
transaction CERE Common Stock Sale $1,248,780 -38,424 -100% $32.50 0 05 Aug 2022 Direct F1, F2
transaction CERE Common Stock Options Exercise $253,009 +19,211 $13.17 19,211 08 Aug 2022 Direct F1
transaction CERE Common Stock Sale $362,626 -9,606 -50% $37.75 9,605 08 Aug 2022 Direct F1
transaction CERE Common Stock Sale $379,398 -9,605 -100% $39.50 0 08 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -38,424 -8.3% $0.000000 422,641 05 Aug 2022 Common Stock 38,424 $13.17 Direct F1, F3
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -19,211 -4.5% $0.000000 403,430 08 Aug 2022 Common Stock 19,211 $13.17 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 - $32.51. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney